Impulsive choice in individuals with comorbid amphetamine use disorder and attention deficit-hyperactivity disorder.
ADHD
Impulsive behavior
Substance use disorder
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
24 07 2023
24 07 2023
Historique:
received:
25
03
2023
accepted:
18
07
2023
medline:
26
7
2023
pubmed:
25
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
Amphetamine use disorder (AMPH) and attention deficit-hyperactivity disorder (ADHD) often co-occur and are associated with poor treatment outcomes. Elevated impulsivity is a core feature in both disorders. Little is known however about the specific neurocognitive profile regarding different facets of impulsivity, and specifically impulsive choice, in comorbid populations. Three groups (ADHD + AMPH, ADHD only and healthy controls (HC)) were assessed with self-reported impulsivity and cognitive tasks of impulsive choice, operationalized as delay aversion (DA) and reflection impulsivity. Twenty-nine participants with comorbid ADHD + AMPH, 25 participants with ADHD only and 116 HC completed screening, including self-rating scales, and cognitive testing. 20, 16 and 114 participants completed computerized cognitive tasks in the ADHD + AMPH group, ADHD group and HC group, respectively. The ADHD + AMPH group reported significantly higher motor, attentional and non-planning impulsiveness, and showed a significantly higher degree of impulsive choice, compared to both groups. There were no differences in task-related impulsiveness between ADHD only and HC. The current findings suggest that individuals with ADHD + AMPH have overall elevated levels of impulsivity compared to individuals with ADHD only. In addition, that ADHD + AMPH is specifically associated with impairments in task-related impulsive choice, which was not found in ADHD only compared to HC. The neurocognitive profile in this specific patient group may represent a need for more systematic screening within healthcare settings in order to develop effective and targeted treatment for comorbid patients. EudraCT, 2012-004298-20.
Sections du résumé
BACKGROUND
Amphetamine use disorder (AMPH) and attention deficit-hyperactivity disorder (ADHD) often co-occur and are associated with poor treatment outcomes. Elevated impulsivity is a core feature in both disorders. Little is known however about the specific neurocognitive profile regarding different facets of impulsivity, and specifically impulsive choice, in comorbid populations.
METHODS
Three groups (ADHD + AMPH, ADHD only and healthy controls (HC)) were assessed with self-reported impulsivity and cognitive tasks of impulsive choice, operationalized as delay aversion (DA) and reflection impulsivity.
RESULTS
Twenty-nine participants with comorbid ADHD + AMPH, 25 participants with ADHD only and 116 HC completed screening, including self-rating scales, and cognitive testing. 20, 16 and 114 participants completed computerized cognitive tasks in the ADHD + AMPH group, ADHD group and HC group, respectively. The ADHD + AMPH group reported significantly higher motor, attentional and non-planning impulsiveness, and showed a significantly higher degree of impulsive choice, compared to both groups. There were no differences in task-related impulsiveness between ADHD only and HC.
CONCLUSIONS
The current findings suggest that individuals with ADHD + AMPH have overall elevated levels of impulsivity compared to individuals with ADHD only. In addition, that ADHD + AMPH is specifically associated with impairments in task-related impulsive choice, which was not found in ADHD only compared to HC. The neurocognitive profile in this specific patient group may represent a need for more systematic screening within healthcare settings in order to develop effective and targeted treatment for comorbid patients.
TRIAL REGISTRATION
EudraCT, 2012-004298-20.
Identifiants
pubmed: 37488536
doi: 10.1186/s12888-023-05034-x
pii: 10.1186/s12888-023-05034-x
pmc: PMC10367266
doi:
Substances chimiques
Amphetamines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
537Informations de copyright
© 2023. The Author(s).
Références
Drug Alcohol Depend. 2013 Apr 1;129(1-2):18-24
pubmed: 23026814
Addiction. 2014 Mar;109(3):440-9
pubmed: 24118269
Harv Rev Psychiatry. 2017 Mar/Apr;25(2):50-64
pubmed: 28272130
Drug Alcohol Depend. 2016 Mar 1;160:97-104
pubmed: 26853151
Drug Alcohol Depend. 2012 Apr 1;122(1-2):11-9
pubmed: 22209385
Curr Drug Abuse Rev. 2017;9(2):76-79
pubmed: 27492358
Pharmacol Biochem Behav. 2018 Jan;164:106-117
pubmed: 28778737
JAMA Psychiatry. 2015 Jun;72(6):593-602
pubmed: 25887096
Am J Psychiatry. 2001 Nov;158(11):1783-93
pubmed: 11691682
Arch Clin Neuropsychol. 2015 Aug;30(5):404-12
pubmed: 26058660
Biol Psychiatry. 2005 Jun 1;57(11):1231-8
pubmed: 15949993
J Psychopharmacol. 2016 Jul;30(7):616-26
pubmed: 27147591
Biol Psychiatry. 2006 Sep 1;60(5):515-22
pubmed: 16448627
Curr Drug Abuse Rev. 2015;8(2):119-33
pubmed: 26373850
BMC Psychiatry. 2021 Sep 18;21(1):458
pubmed: 34537043
J Addict Med. 2014 Sep-Oct;8(5):368-76
pubmed: 25187977
J Affect Disord. 2001 May;64(2-3):203-16
pubmed: 11313087
Eur Addict Res. 2009;15(1):10-8
pubmed: 19052458
Eur Addict Res. 2020;26(4-5):295-305
pubmed: 32659779
Nat Rev Neurosci. 2017 Feb 17;18(3):158-171
pubmed: 28209979
Addict Behav. 2018 May;80:154-160
pubmed: 29407687
Clin Psychol Rev. 2011 Aug;31(6):965-82
pubmed: 21733491
Psychopharmacology (Berl). 2021 Jul;238(7):1753-1763
pubmed: 33638699
J Neurosci. 1999 Oct 15;19(20):9029-38
pubmed: 10516320
Eur Addict Res. 2015;21(3):131-43
pubmed: 25675959
Br J Psychiatry. 2013 Jul;203(1):35-43
pubmed: 23703315
Clin Psychol Rev. 2016 Feb;43:162-74
pubmed: 26602954
Psychiatry Res. 2016 Dec 30;246:656-662
pubmed: 27842945
Drug Alcohol Rev. 2015 Nov;34(6):683-93
pubmed: 25790353
Psychol Med. 2019 Jan;49(2):217-223
pubmed: 29530108
Drug Alcohol Depend. 2014 Jan 1;134:158-166
pubmed: 24156882